彪马

Puma Biotechnology Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 4% premium over our quantitative fair value estimate of $9.44 per share; however, this estimate should be taken with a pinch of salt due to its medium uncertainty rating.

The company's lack of growth weakens our estimated valuation. Stagnant revenue and earnings growth indicates a company's challenges in increasing market share and profitability. Reflecting the firm's growth is its EPS 5-year growth of -28.7%, which lies in the bottom 10% compared with global peers. On a relative basis, EPS growth has lagged over the last five years, which contributes to our view that shares are overvalued.

Alternatively, the company's profitability is reassuring. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 6.9%, for example, falls in the top 40% compared with global peers. This suggests that it is generating substantial earnings relative to its share price, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.